Goldman Sachs
TNXP icon

Goldman Sachs’s Tonix Pharmaceuticals TNXP Stock Holding History

Goldman Sachs’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$730K Buy
53,055
+26,247
+98% +$404K ﹤0.01% 5325
2025
Q4 		$419K Buy
26,808
+14,086
+111% +$260K ﹤0.01% 5702
2025
Q3 		$307K Buy
+12,722
New +$472K ﹤0.01% 5735
2022
Q4 		– Sell
-2
Closed -$18K – 6270
2022
Q3 		$18K Buy
2
+1
+100% +$24.5K ﹤0.01% 5956
2022
Q2 		$17K Hold
1
– – ﹤0.01% 6202
2022
Q1 		$98K Hold
1
– – ﹤0.01% 6115
2021
Q4 		$219K Hold
1
– – ﹤0.01% 5849
2021
Q3 		$371K Buy
+1
New +$487K ﹤0.01% 5370
2021
Q2 		– Hold
0
– – – 6100
2021
Q1 		– Hold
0
– – – 5395
2017
Q1 		– Hold
0
– -$46K – 7003
2016
Q4 		– Hold
0
– – – 6407
2016
Q3 		– Hold
0
– – – 6854
2016
Q2 		– Hold
0
– – – 6646
2014
Q1 		– Hold
0
– -$109K – 6933
2013
Q4 		– Hold
0
– – – 6247

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Goldman Sachs's TNXP Position: Q1 2026 in Review

Goldman Sachs increased its Tonix Pharmaceuticals (TNXP) stake by 98% in Q1 2026, buying an estimated $404K and bringing the position to 53,055 shares worth $730K. The position accounts for ﹤0.01% of the portfolio, ranked #5325.

Goldman Sachs first reported a position in TNXP in Q3 2021 and has held it in 8 quarters since. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Goldman Sachs held 53,055 shares of Tonix Pharmaceuticals worth $730K as of Q1 2026.
  • Goldman Sachs bought 26,247 Tonix Pharmaceuticals shares in Q1 2026, an estimated $404K.
  • Tonix Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5325 holding.
  • Goldman Sachs first reported a position in Tonix Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.